by hipockets | April 15, 2015 10:54 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2015/04/microblog-medical-devices-and-other-interesting-usually-biotech-stocks/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
$MBOT 1/2p – https://www.stockgumshoe.com/2016/04/microblog-ai-artificial-intelligence/comment-page-2/#comment-4953290
And
https://www.stockgumshoe.com/2016/05/microblog-ztne-rktz/comment-page-2/#comment-4953395
And Rodman and Renshaw Conference webcast link Microbot Medical Inc (MBOT) Healthcare http://www.wsw.com/webcast/rrshq27/mbot
https://www.stockgumshoe.com/2017/09/rodman-and-renshaw-presentation-notes-day-two/comment-page-1/#comment-4950248
edit in after 2 links will follow
Long GREAT Gummune!
Let us use this thread for non #ZKSS Medical Devices in the future please!
$BIOP in see. https://www.stockgumshoe.com/2016/05/microblog-ztne-rktz/comment-page-2/#comment-4953395
$MRIC,
$ no ticker
My son’s high school in Northwest Indiana is having a seminar on heroin next week.. As someone who went to school in the 70s I find this really depressing.. The government has totally failed us on this.. New approaches needed.. Nothing political intended. Just don’t know how it came back and is now out of control..
Hurricane Damage in Puerto Rico Leads to Fears of Drug Shortages Nationwide
By KATIE THOMAS and SHEILA KAPLANOCT. 4, 2017
https://www.nytimes.com/2017/10/04/health/puerto-rico-hurricane-maria-pharmaceutical-manufacturers.html
http://www.prnewswire.com/news-releases/syndax-announces-dosing-of-first-patient-in-pivotal-trial-of-entinostat-for-the-treatment-of-advanced-or-recurrent-breast-cancer-in-japan-by-partner-kyowa-hakko-kirin-300531613.html
$MRIC – MRI Interventions Announces Joseph Burnett As New President and CEO http://ir.stockpr.com/mriinterventions/news/detail/947
$TRXC – TransEnterix Announces Dismissal of Federal Securities Class Action http://www.businesswire.com/news/home/20171009005329/en/
$MRIC 8K -CEO Grillo resigning http://ir.stockpr.com/mriinterventions/all-sec-filings/content/0001534424-17-000429/f17-1202.htm
– 424B3: Prospectus filed pursuant to Rule 424(b)(3) http://ir.stockpr.com/mriinterventions/all-sec-filings/content/0001534424-17-000430/f17-1203.htm
$LUNG – PROLUNG SETS TERMS FOR $7 MILLION IPO
October 17, 2017
ProLung, which is developing a test that predicts early-stage risk of lung cancer, announced terms for its IPO on Tuesday.
The Salt Lake City, UT-based company plans to raise $7 million by offering 0.93 million shares at a price range of $7 to $8. At the midpoint of the proposed range, ProLung would command a market value of $36 million.
Because the company’s post-IPO market value is below $50 million, it will be excluded from our IPO stats
The pre-revenue company was founded in 2004 and plans to list on the Nasdaq under the symbol LUNG. Maxim Group LLC and Aegis Capital Corp. are the joint bookrunners on the deal.
Relevant Profile: LUNG https://www.renaissancecapital.com/Profile/LUNG/ProLung/IPO
ht chris
$TRXC np – Form SC 13D/A / Amended General Statement of Beneficial Ownership http://ir.transenterix.com/secfiling.cfm?filingid=950142-17-2071&CIK=876378
all SEC filings: http://ir.transenterix.com/sec.cfm
$MBOT long –
Technical Snapshots for These Medical Supplies Stocks — Microbot Medical, C.R. Bard, Cooper Cos., and Waters PR Newswire
November 08, 2017 1:01 pm ET
Microbot Medical Inc. Receives Additional Government Grant for Development of its Self-Cleaning Shunt Globe Newswire
November 08, 2017 9:13 am ET
Microbot Medical Inc, Inst Holders, 3Q 2017 (MBOT) Dow Jones
October 21, 2017 8:08 am ET
Microbot Medical Inc, Inst Holders, 3Q 2017 (MBOT) Dow Jones
October 12, 2017 11:10 am ET
Stock Performance Review on Medical Supplies Industry — Microbot Medical, Cooper, Waters, and C.R. Bard PR Newswire
October 05, 2017 6:08 pm ET
*Microbot Medical Inc. Director Bornstein Sells 53,000 @ Avg Price: $1.20 -Form4 Benzinga Seems to be heating up! hmmm #DYODDNIAG 🙂
🙂 Have some wonderful ThanksGiving $HALO dayz and beyond! 🙂 Best2ALL 🙂
LexaGene Completes Prototype Assembly for Soon-To-Be First Fully Automated, Open-Access
Pathogen Detection System http://lexagene.com/wp-content/uploads/2017/11/LXG30November2017-Prototype.pdf
New Technology Will Revolutionize Pathogen Detection Across Food Safety, Veterinary and
Human Clinical Diagnostics
VANCOUVER, British Columbia, Nov. 30, 2017 – LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V:
LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen
detection, has completed the assembly of its prototype for what will be the world’s first fully
automated, open-access and on-site pathogen detection platform. The technology will be
capable of screening for up to 22 pathogens at once and deliver results in just one hour – as
opposed to three to five days, which is typical for standard methods. It is also designed be used
by people with no knowledge of automated instrumentation, microbiology or molecular biology.
“The completion of our alpha prototype marks a very important milestone for LexaGene, and
this instrument is expected to provide fast and accurate pathogen detection that will be useful
for many different industries – from food safety to veterinary and human clinical diagnostics,”
said Dr. Jack Regan, LexaGene’s CEO and Founder. “Now, we are turning our attention to
maximizing the instrument’s performance so that end-users can better manage the care of
their patients, and food safety officers can better prevent illnesses from occurring in the first
place.”…
Stellar Biotechnologies Inc. (SBOT)FORM 8-K | Current report
Dec. 1, 2017 8:01 AM|About: Stellar Biotechnologies Inc. (SBOT)
https://seekingalpha.com/filing/3784295?
Mazor Robotics CEO suspected of insider trading; shares down 14% premarket
Dec. 4, 2017 7:31 AM ET|About: Mazor Robotics Ltd. (MZOR)|By: Douglas W. House, SA News Editor
Mazor Robotics (NASDAQ:MZOR) slumps 14% premarket on modestly higher volume in response to an investigation by the Israeli Securities Authority (ISA) into possible insider trading by CEO Ori Hadomi.
Specifically, the ISA is probing into an alleged leak of information to close associates about its distribution deal with Medtronic. Authorities searched Mr. Hadomi’s home and confiscated his cell phone in May.
https://seekingalpha.com/news/3315944-mazor-robotics-ceo-suspected-insider-trading-shares-14-percent-premarket?
$MRIC MRI Interventions ClearPoint® Neuro Navigation System Utilized for the First Time in Minnesota
Click here to read the full article https://ir.stockpr.com/mriinterventions/company-news/detail/953
SoGiAm,
saw your couple of days old post on Dr. KSS main tread “$DDD np – DDD: 3D Systems +6.4% on Virtual Surgical Planning partnership https://seekingalpha.com/news/3323229-3d-systems-plus-6_4-percent-virtual-surgical-planning-partnership”
Would love to hear your thoughts on this strategic step or company itself – or both 🙂 What do you think?
yours, Finn
$MRIC, $VYGR – MRI Interventions Recognizes FDA Clearance of Voyager’s Investigational New Drug Application for VY-AADC Allowing its Pivotal Program to Begin for Advanced Parkinson’s Disease
Click here to read the full article https://ir.stockpr.com/mriinterventions/company-news/detail/954
$VLRX, TNDM fp > I am long Tandem and it is y largest percentage gainer this year. Both concerns focus on Type II DM delivery systems.
Valeritas Holdings, Inc. is a commercial-stage medical technology company. The Company is focused on developing technologies for Type 2 diabetes. The Company’s product, the V-Go Wearable Insulin Delivery Device (V-Go), is an insulin delivery device that helps patients with Type 2 diabetes requiring insulin to maintain their target blood glucose goals. V-Go is a disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. The Company has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.